Alnylam market cap at 7.5B; IMGN at 550M. Is RNAi ever gonna work?
I thought FDA banned snake oil very early on. Why are there still so many biotech companies peddling snake oil? That's right...they just need to be somewhat properly labelled; they don't really need to work as advertised. Is IMGN also a snake oil company that we have invested in?
On NPS' side, one analyst mentioned 150M if NPS sells to another bidder; I have seen 200M mentioned on this board. 200M will be covered by ~2$ per share. Although unlikely given the info available out there, a 48$ bid could pretty much cover the break up fee. In fantasyland, Shire will counterbid and tack an additional $2 pps, getting the buyout pps to $50. I'm very much tempted to hold on to some shares for that fantasyland scenario.
What's more curious is why Takeda didn't pick SGEN. ADC deals with IMGN and SGEN must be getting too pricey to do these days.
With the lack of damage control and lack of insider buying from Junius and the boys when the pps was sub6, I am now joining you in wanting to throw them all overboard.
In one paper, by 10 days of in vitro propagated TILS are depleted within 10 days in vivo. I think that is very promising.
Still, aside from safety concerns, the expense of CARTs is so much more.
Specificity makes a huge difference if the targets are expressed only in cancer cells. But that's a big if since we know that many Ab targets are also expressed in normal cells. If the CAR T-cells have a short life span, patients can get "cured" of their cancer by the time those Tcells die.
As a biotech investor, I'm still trying to get a complete picture of the risks in CAR-T, and whether they are very well worth it. If they can engineer an expression switch that can be turned on and off, then that will be great. CD19, Kite's, target is somewhat risky as it is required for normal B-cell maturation, if I am not mistaken. However, if the CAR-Ts die when they are done with their killing spree, then that will be great. It may also come down to dosing, if they know the CAR-Ts will die. What is the life span of those CAR-Ts anyway?
clinicaltrials dot gov shows June 15 as primary completion and Oct for completion. They will probably release results after June 15, but have to do more observational studies past that. Maybe for AEs.
Once you get the engineered T-cells in there, how will scientists get them out if they go crazy? Is there an off switch that they have built in?
As long as there are sellers at low prices, those who know something would keep trying to buy at low prices. The volume they are buying won't be enough to move the pps, unless an investigator gets wined and dined by a hedgie, as happens often.
Since patients no longer respond to Lucentis/Avastin, if an investigator/clinical assistants/patients/relatives see a response, odds are it is due to Isonep.
Did the completion date get pushed back again? I am now seeing Oct.
Beaten down IMGN. Or you can wait until it gets beaten down more.
I would think that if there was another interested buyer, it would have snapped NPS up when Shire was not able to buy NPS because of the pending Abbvie activity. Then again, it's still possible that another buyer might step in.after Natpara gets approved.
Congrats to all holders.
Comparable efficacy with Fabrazyme at lower dose and 85% of subjects developed antibodies against aGAL in Fabrazyme, while only 33% did with PRX-102.
I wish Protalix will develop another product for enzyme replacement therapy for a rare disease.
I was gonna tell you to sell ARNA on yesterday's pop. Good luck on that one. Belviq won't sell, but that S1P drug may, but will take a very long time.
This month's earnings report. 25.7M from Novartis and maybe 5M or more from Kadcyla sales, would more than double last quarter's revenue of 13.2M .
6 wk Sovaldi + 3102 is impressive, if results extend to SVR12. What's the ultimate goal for these combos? 4 weeks maybe? Unless SAEs come up, there is no reason why 3102, for use with Sovaldi, won't get FDA approval. Just can't price 3102 at a premium, and Gilead can always reduce the price of Harvoni.
Given that Viekira is a 4 tablet regimen with ribavirin, and it actually sells, 3102 + 2684 + ribavirin may be able to surpass that. Add sovaprevir to that and that may even be better. I agree that too much is unknown right now with 2684. Too early in the clinic.
Add 3422 to the pipeline, and complement inhibitors, and maybe ACHN's not too bad at current market cap. Upside is probably still reasonable at current pps. Let's see the sovaldi + 3102 SVR12.
Remember when we only had sovaprevir and no nuc and we thought ACHN won't really need a nuc? Do you strongly believe now that a nuc will be absolutely necessary for HCV cure? Can't ACHN do it with just 2684 and 3102, and match Harvoni?
I'm also having doubts about deuterated 3422, but then again I've already made enough from ACHN and have very little at stake now. But I can't ignore 2684 and 3102 by themselves, or perhaps when combined with sovaldi or even 3422.